Rosière Rémi, Gelbcke Michel, Mathieu Véronique, Van Antwerpen Pierre, Amighi Karim, Wauthoz Nathalie
Laboratory of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), B-1050 Brussels, Belgium.
Laboratory of Therapeutic Chemistry, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), B-1050 Brussels, Belgium.
Int J Oncol. 2015 Sep;47(3):1131-42. doi: 10.3892/ijo.2015.3092. Epub 2015 Jul 20.
Besides the numerous advantages of a chemotherapy administered by the inhalation route for lung cancer therapy, dry powder for inhalation (DPI) offers many advantages compared to other techniques and seems to be a technique that is well-adapted to an anticancer treatment. DPI formulations were developed using the cytotoxic drug temozolomide and a new folate-grafted self-assembling copolymer, a conjugate of three components, folate-polyethylene glycol-hydrophobically-modified dextran (F-PEG-HMD). F-PEG-HMD was synthesized using carbodiimide-mediated coupling chemistry in three main steps. F-PEG-HMD was characterized by 1H-NMR, mass spectrometry and thermal analysis. F-PEG-HMD presented a critical micellar concentration in water of 4x10-7 M. F-PEG-HMD nanomicelles were characterized by a trimodal particle size distribution with Z-average diameter of 83±1 nm in water. Temozolomide-loaded nanomicelles were prepared by solubilization of F-PEG-HMD in the presence of temozolomide. Temozolomide solubility in water was increased in the presence of F-PEG-HMD (2-fold increase in molar solubility) which could potentially lead to increased local concentrations in the tumor site. The temozolomide-loaded F-PEG-HMD nanomicelles were characterized by a Z-average diameter of ~50 to ~60 nm, depending on the F-PEG-HMD concentration used. The nanomicelles were then spray-dried to produce dry powders. Temozolomide remained stable during all the formulation steps, confirmed by similar in vitro anticancer properties for the DPI formulations and a raw temozolomide solution. Two of the developed DPI formulations were characterized by good aerodynamic properties (with a fine particle fraction of up to 50%) and were able to release the F-PEG-HMD nanomicelles quickly in aqueous media. Moreover, in vitro, the two DPI formulations showed wide pulmonary deposition in the lower respiratory tract where adenocarcinomas are more often found. The present study, therefore, shows that F-PEG-HMD-based dry powders for inhalation could constitute an interesting drug delivery system able to release nanomicelles that are useful in adenocarcinomas that overexpress folate receptors.
除了吸入途径给药化疗在肺癌治疗方面具有众多优势外,与其他技术相比,吸入用干粉(DPI)具有许多优点,似乎是一种非常适合抗癌治疗的技术。DPI制剂是使用细胞毒性药物替莫唑胺和一种新的叶酸接枝自组装共聚物(一种由叶酸 - 聚乙二醇 - 疏水改性葡聚糖(F - PEG - HMD)三种成分组成的共轭物)开发的。F - PEG - HMD通过碳二亚胺介导的偶联化学分三个主要步骤合成。F - PEG - HMD通过1H - NMR、质谱和热分析进行表征。F - PEG - HMD在水中的临界胶束浓度为4×10 - 7 M。F - PEG - HMD纳米胶束的特征是具有三峰粒径分布,在水中的Z平均直径为83±1 nm。载有替莫唑胺的纳米胶束是通过在替莫唑胺存在下将F - PEG - HMD溶解来制备的。在F - PEG - HMD存在下,替莫唑胺在水中的溶解度增加(摩尔溶解度增加2倍),这可能会导致肿瘤部位局部浓度增加。载有替莫唑胺的F - PEG - HMD纳米胶束的Z平均直径约为50至60 nm,具体取决于所使用的F - PEG - HMD浓度。然后将纳米胶束喷雾干燥以生产干粉。通过DPI制剂和替莫唑胺原液具有相似的体外抗癌特性,证实替莫唑胺在所有制剂步骤中保持稳定。所开发的两种DPI制剂的特征是具有良好的空气动力学性能(细颗粒分数高达50%),并且能够在水性介质中快速释放F - PEG - HMD纳米胶束。此外,在体外,这两种DPI制剂在下呼吸道显示出广泛的肺部沉积,而下呼吸道更常发现腺癌。因此,本研究表明,基于F - PEG - HMD的吸入用干粉可能构成一种有趣的药物递送系统,能够释放对过表达叶酸受体的腺癌有用的纳米胶束。